drugset / Trial / NCT05819060
The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab
NaSingle-groupOpen-labelTreatment
Summary
The study will be a Prospective, Single-arm, Phase Ⅱ Clinical Study. This study intends to explore the efficacy and safety of Fuzuloparib combined with bevacizumab in the maintenance treatment of patients with platinum-sensitive ovarian cancer. The progression-free survival, OS, and safety were evaluated based on RECIST V1.1.
Timeline
- Start
- 2023-04-30
- Primary completion
- 2024-09-30
- Completion
- 2025-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | — |
| Subject | Fluzoparib | Small molecule | 100 mg | — |
| Subject | Fluzoparib | Small molecule | 150 mg | — |